SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Psychopharmacology
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
0269881106065907v1
20/6/842    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (16)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Yang, J.
Right arrow Articles by Rostami-Hodjegan, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yang, J.
Right arrow Articles by Rostami-Hodjegan, A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA

Jiansong Yang

Masoud Jamei

Amir Heydari

Karen R. Yeo

Simcyp Limited, Sheffield, UK

Rafael de la Torre

Magí Farré

Institut Municipal d'Investigació Mèdica, Barcelona, Spain

Geoffrey T. Tucker

Amin Rostami-Hodjegan

University of Sheffield, Sheffield, UK

The aim of this study was to model the in vivo kinetic consequences of mechanism-based inhibition (MBI) of CYP2D6 by 3,4 methylenedioxymethamphetamine (MDMA, ecstasy). A model with physiologically-based components of drug metabolism was developed, taking account of change in the hepatic content of active CYP2D6 due to MBI by MDMA. Based on the in vitro information, plasma concentration time profiles of MDMA after various doses were computed and compared with reported observations. The analysis suggested that a typical recreational MDMA dose could inactivate most hepatic CYP2D6 within an hour, and the return to a basal level of CYP2D6 could take at least 10 days. Thus, the genetic polymorphism of CYP2D6 and coadministration of CYP2D6 inhibitors may have less impact on MDMA pharmacokinetics and the risk of acute toxicity than previously thought. This is consistent with clinical observations that indicate no obvious link between inherited CYP2D6 deficiency and acute MDMA intoxication.

Key Words: ecstasy • inactivation • MDMA • mechanism-based inhibition • modelling

This version was published on November 1, 2006

Journal of Psychopharmacology, Vol. 20, No. 6, 842-849 (2006)
DOI: 10.1177/0269881106065907
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
L. Xu, Y. Chen, Y. Pan, G. L. Skiles, and M. Shou
Prediction of Human Drug-Drug Interactions from Time-Dependent Inactivation of CYP3A4 in Primary Hepatocytes Using a Population-Based Simulator
Drug Metab. Dispos., December 1, 2009; 37(12): 2330 - 2339.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. Gabrielsson and A. R. Green
Quantitative Pharmacology or Pharmacokinetic Pharmacodynamic Integration Should Be a Vital Component in Integrative Pharmacology
J. Pharmacol. Exp. Ther., December 1, 2009; 331(3): 767 - 774.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
X. Perfetti, B. O'Mathuna, N. Pizarro, E. Cuyas, O. Khymenets, B. Almeida, M. Pellegrini, S. Pichini, S. S. Lau, T. J. Monks, et al.
Neurotoxic Thioether Adducts of 3,4-Methylenedioxymethamphetamine Identified in Human Urine After Ecstasy Ingestion
Drug Metab. Dispos., July 1, 2009; 37(7): 1448 - 1455.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. W. Grimm, H. J. Einolf, S. D. Hall, K. He, H.-K. Lim, K.-H. J. Ling, C. Lu, A. A. Nomeir, E. Seibert, K. W. Skordos, et al.
The Conduct of in Vitro Studies to Address Time-Dependent Inhibition of Drug-Metabolizing Enzymes: A Perspective of the Pharmaceutical Research and Manufacturers of America
Drug Metab. Dispos., July 1, 2009; 37(7): 1355 - 1370.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Mueller, F. T. Peters, H. H. Maurer, U. D. McCann, and G. A. Ricaurte
Nonlinear Pharmacokinetics of ({+/-})3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") and Its Major Metabolites in Squirrel Monkeys at Plasma Concentrations of MDMA That Develop After Typical Psychoactive Doses
J. Pharmacol. Exp. Ther., October 1, 2008; 327(1): 38 - 44.
[Abstract] [Full Text] [PDF]


Advertisement